These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 18431823)

  • 21. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation.
    Ross JS; Hill KP; Egilman DS; Krumholz HM
    JAMA; 2008 Apr; 299(15):1800-12. PubMed ID: 18413874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The problem of new uses.
    Eisenberg RS
    Yale J Health Policy Law Ethics; 2005; 5(2):717-39. PubMed ID: 16052897
    [No Abstract]   [Full Text] [Related]  

  • 23. [Ghostwriting].
    Haug C
    Tidsskr Nor Laegeforen; 2008 May; 128(9):1039. PubMed ID: 18451881
    [No Abstract]   [Full Text] [Related]  

  • 24. Crossing the line: part 2.
    Blaivas JG
    Neurourol Urodyn; 2005; 24(1):1. PubMed ID: 15593361
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical research law in Jordan.
    Treish IM
    Dev World Bioeth; 2009 Aug; 9(2):97. PubMed ID: 19645717
    [No Abstract]   [Full Text] [Related]  

  • 26. Editorial overview: from Vioxx to Luckenbach: drug discovery at a crossroads.
    Williams M
    Curr Opin Investig Drugs; 2005 Jan; 6(1):17-20. PubMed ID: 15675599
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug firms back-pedal on direct advertising.
    Nature; 2005 Aug; 436(7053):910-1. PubMed ID: 16107811
    [No Abstract]   [Full Text] [Related]  

  • 28. Drug lawsuits building. Merck, Pfizer facing charges of misrepresentation.
    Benko LB
    Mod Healthc; 2006 Apr; 36(15):16. PubMed ID: 16669517
    [No Abstract]   [Full Text] [Related]  

  • 29. Lapses at the new England journal of medicine.
    Smith R
    J R Soc Med; 2006 Aug; 99(8):380-2. PubMed ID: 16893926
    [No Abstract]   [Full Text] [Related]  

  • 30. Merck to pay $5bn in rofecoxib claims.
    Charatan F
    BMJ; 2007 Nov; 335(7628):1011. PubMed ID: 18006982
    [No Abstract]   [Full Text] [Related]  

  • 31. Causation, Vioxx, and legal issues.
    Green MD
    Science; 2005 Nov; 310(5750):973. PubMed ID: 16284163
    [No Abstract]   [Full Text] [Related]  

  • 32. Merck's actions surrounding Vioxx.
    Heinley M
    PLoS Med; 2006 Jun; 3(6):e286; author reply e285. PubMed ID: 16789808
    [No Abstract]   [Full Text] [Related]  

  • 33. Quebec allows Vioxx class-action suit.
    Sibbald B
    CMAJ; 2007 Jan; 176(1):20. PubMed ID: 17200378
    [No Abstract]   [Full Text] [Related]  

  • 34. Guinea-pigging: healthy human subjects for drug safety trials are in demand. But is it a living?
    Elliott C
    New Yorker; 2008 Jan; ():36-41. PubMed ID: 18265451
    [No Abstract]   [Full Text] [Related]  

  • 35. Vioxx may go back on sale after scraping past FDA panel.
    Wadman M
    Nature; 2005 Feb; 433(7028):790. PubMed ID: 15729304
    [No Abstract]   [Full Text] [Related]  

  • 36. The law. Vioxx verdict: too little or too much science?
    Lawler A
    Science; 2005 Sep; 309(5740):1481. PubMed ID: 16141043
    [No Abstract]   [Full Text] [Related]  

  • 37. Why is this woman smiling? The hard sell of bad medicine.
    Bloice C
    Revolution (Oakl); 2005; 6(1):22-9. PubMed ID: 15822700
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug company trials come under increasing scrutiny.
    Loewenberg S
    Lancet; 2008 Jan; 371(9608):191-2. PubMed ID: 18217230
    [No Abstract]   [Full Text] [Related]  

  • 39. Anticipating a Vioxx defense strategy: will corporate honesty be enough?
    Willis KD
    Tort Trial Insur Pract Law J; 2006; 41(4):1163-78. PubMed ID: 17091567
    [No Abstract]   [Full Text] [Related]  

  • 40. 94% of patients suing Merck over rofecoxib agree to company's offer.
    Charatan F
    BMJ; 2008 Mar; 336(7644):580-1. PubMed ID: 18340064
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.